4D Molecular Therapeutics (FDMT) Leases: 2021-2025
Historic Leases for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Sep 2025 value amounting to $18.9 million.
- 4D Molecular Therapeutics' Leases fell 13.12% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.9 million, marking a year-over-year decrease of 13.12%. This contributed to the annual value of $21.1 million for FY2024, which is 82.63% up from last year.
- According to the latest figures from Q3 2025, 4D Molecular Therapeutics' Leases is $18.9 million, which was down 3.78% from $19.6 million recorded in Q2 2025.
- 4D Molecular Therapeutics' Leases' 5-year high stood at $21.8 million during Q3 2024, with a 5-year trough of $10.7 million in Q2 2024.
- Over the past 3 years, 4D Molecular Therapeutics' median Leases value was $12.7 million (recorded in 2023), while the average stood at $15.6 million.
- Per our database at Business Quant, 4D Molecular Therapeutics' Leases declined by 13.47% in 2024 and then spiked by 83.84% in 2025.
- 4D Molecular Therapeutics' Leases (Quarterly) stood at $14.6 million in 2021, then decreased by 10.14% to $13.1 million in 2022, then decreased by 11.82% to $11.5 million in 2023, then surged by 82.63% to $21.1 million in 2024, then fell by 13.12% to $18.9 million in 2025.
- Its last three reported values are $18.9 million in Q3 2025, $19.6 million for Q2 2025, and $20.4 million during Q1 2025.